10-K: Krystal Biotech's VYJUVEK Drives Strong 2025 Revenue Growth

Krystal Biotech's 2025 annual report highlights significant revenue growth from its gene therapy VYJUVEK, expanded global approvals, and positive clinical progress across its pipeline, while navigating increased operating expenses.

Summary

• Net product revenue for VYJUVEK reached $389.1 million for the year ended December 31, 2025, a substantial increase from $290.5 million in 2024 and $50.7 million in 2023.
• Cumulative net product revenue since VYJUVEK's launch in August 2023 totaled $730.3 million.
• The gross margin for VYJUVEK sales was 94% for the year ended December 31, 2025.
• VYJUVEK received marketing authorization in the European Union in April 2025 and Japan in July 2025 for the treatment of dystrophic epidermolysis bullosa (DEB), with commercial launches in Germany (August 2025), France (October 2025), and Japan (October 2025).
• The FDA approved a label update for VYJUVEK in September 2025, expanding treatment eligibility to DEB patients from birth and allowing administration by a healthcare professional, caregiver, or directly by the patient at home.
• KB407 (Cystic Fibrosis) showed positive interim clinical results from the Phase 1 CORAL-1 study (Cohort 3) in January 2026, confirming successful lung delivery and CFTR protein expression (29.4% to 42.1% transduction). A repeat dosing study (CORAL-3) was submitted to the FDA in December 2025 and is expected to begin enrollment in the first half of 2026.
• KB408 (Alpha-1 Antitrypsin Deficiency) presented interim clinical data from the Phase 1 SERPENTINE-1 study (Cohort 2) in December 2024, demonstrating successful gene delivery, AAT expression, and reduction in free neutrophil elastase. Enrollment in a repeat dosing cohort (2B) is ongoing, with data expected in 2026.
• KB803 (Ocular Complications of DEB) initiated a Phase 3 registrational study (IOLITE) in June 2025, with enrollment anticipated to complete in the first half of 2026 and top-line results expected in late 2026.
• KB801 (Neurotrophic Keratitis) received FDA platform technology designation in October 2025, and its Phase 1/2 EMERALD-1 study was amended to serve as a registrational trial, with top-line data expected in 2026.
• KB111 (Hailey-Hailey Disease) received FDA Fast Track Designation in January 2026, and a registrational study is expected to initiate in the second half of 2026.
• Inhaled KB707 (Solid Tumors, specifically NSCLC) demonstrated early monotherapy activity in the KYANITE-1 Phase 1/2 study, achieving an Objective Response Rate (ORR) of 36% and a Disease Control Rate (DCR) of 54% in heavily pre-treated NSCLC patients as of June 2025. FDA feedback suggests a single Phase 3 registrational study in combination with chemotherapy may be sufficient for approval.
• Intratumoral KB707 (OPAL-1) enrollment was paused in August 2025 to prioritize inhaled KB707 development.
• KB304 (Aesthetic Wrinkles) reported positive safety and efficacy results from the Phase 1 PEARL-2 study in July 2025, showing significant improvements in skin attributes. A Phase 2 study is expected to initiate in 2027.
• Net income for the year ended December 31, 2025, was $204.8 million, compared to $89.2 million in 2024 and $10.9 million in 2023.
• Cash, cash equivalents, and short-term investments totaled approximately $827.8 million as of December 31, 2025.
• The company fully utilized its federal net operating losses in 2025 and recognized a $51.2 million income tax benefit from the release of a valuation allowance on deferred tax assets.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, driven by robust commercial performance of VYJUVEK and significant positive clinical and regulatory advancements across a broad pipeline, despite increased operating expenses and ongoing pricing negotiations in some international markets.

Positives

• Strong revenue growth for VYJUVEK: $389.1 million in 2025, a 34% increase from $290.5 million in 2024, indicating successful commercialization and market penetration.
• High gross margin of 94% for VYJUVEK in 2025, reflecting efficient production and strong pricing power.
• Global regulatory approvals for VYJUVEK in the EU (April 2025) and Japan (July 2025), significantly expanding market reach beyond the United States.
• FDA label expansion for VYJUVEK (September 2025) to include DEB patients from birth and allow home administration, enhancing patient access and convenience.
• Positive interim clinical data for KB407 (CF) showing successful lung delivery and CFTR protein expression, supporting progression to a potentially registrational study.
• Positive interim clinical data for KB408 (AATD) demonstrating successful gene delivery, AAT expression, and reduction in free neutrophil elastase, indicating therapeutic potential.
• FDA granted platform technology designation to the HSV-1 viral vector used in KB801, recognizing the reproducibility and scalability of the company's core technology.
• KB801 (Neurotrophic Keratitis) Phase 1/2 EMERALD-1 study was amended to serve as a registrational trial, potentially accelerating its path to market.
• KB111 (Hailey-Hailey Disease) received Fast Track Designation from the FDA, which may expedite its development and review process.
• Inhaled KB707 (NSCLC) showed promising early evidence of monotherapy activity with a 36% Objective Response Rate and 54% Disease Control Rate in heavily pre-treated patients.
• FDA feedback suggests a single Phase 3 registrational study for inhaled KB707 in combination with chemotherapy for NSCLC may be sufficient for approval, streamlining the development pathway.
• Positive safety and efficacy results for KB304 (aesthetic wrinkles) in PEARL-2, demonstrating significant improvements in multiple skin aesthetic attributes.
• Significant increase in net income to $204.8 million in 2025, indicating strong profitability.
• Robust cash position with $827.8 million in cash, cash equivalents, and short-term investments as of December 31, 2025, providing financial stability.
• Release of a $51.2 million valuation allowance on deferred tax assets due to sustained profitability, improving the company's balance sheet.

Negatives

• Increased operating expenses across all categories, including Cost of Goods Sold ($23.0 million), Research and Development ($58.0 million), and Selling, General and Administrative ($146.7 million) for 2025.
• Pricing negotiations for VYJUVEK in Germany are expected to continue until at least the second half of 2026, and until 2027 in France, potentially delaying full market access and revenue realization in these key European markets.
• Enrollment in the intratumoral KB707 (OPAL-1) study was paused in August 2025, indicating a reprioritization or potential setback for this specific oncology program.
• A cybersecurity incident in 2024 affecting a specialty pharmacy provider delayed reimbursement approvals and had a negative impact on product revenue.
• The company is subject to a derivative complaint filed in September 2025 alleging excessive non-employee director compensation, which could lead to legal costs and reputational harm.
• Received subpoenas from the U.S. Department of Justice regarding its sponsored genetic testing program and commercial practices for VYJUVEK, with the outcome and potential loss being uncertain.

Risks

• Substantial dependence on the commercial success of VYJUVEK.
• Inability to successfully discover, develop, and commercialize additional product candidates, impairing business expansion and strategic objectives.
• Significant competition in an environment of rapid technological change, with competitors potentially achieving regulatory approval sooner or developing more effective therapies.
• Potential for product liability lawsuits, leading to substantial liabilities and limitations on commercialization.
• Adverse effects from healthcare legislative reform measures, including price controls, reduced access to care, and reimbursement restrictions (e.g., Inflation Reduction Act, One Big Beautiful Bill Act).
• Compliance risks with federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws, potentially leading to substantial penalties.
• Internal computer systems or those of third parties may fail or suffer cybersecurity incidents, damaging reputation, exposing to liability, and disrupting operations.
• International operations expose the company to business, regulatory, political, operational, financial, pricing, reimbursement, and economic risks.
• Inability to manage expected growth in the scale and complexity of operations, potentially impacting performance.
• Delays or failures in advancing product candidates through clinical trials, obtaining regulatory approval, or ultimately commercializing them.
• VYJUVEK or product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval or limit commercial potential.
• Reliance on third parties to conduct certain preclinical studies and clinical trials, with risks of non-performance, missed deadlines, or non-compliance.
• Delays in obtaining regulatory approvals for manufacturing processes or facilities, or disruptions in the manufacturing process.
• Dependence on a limited number of third-party suppliers for components and materials used in manufacturing and commercial supply.
• Contamination in, or changes to, the manufacturing process, shortages of raw materials, or failure of key suppliers.
• Limited experience as a commercial company, potentially leading to unsuccessful or less successful sales, marketing, and distribution.
• Inability to maintain agreements with third parties to distribute VYJUVEK.
• Market opportunities for VYJUVEK or product candidates may be smaller than anticipated, adversely impacting product revenue.
• Government price controls or other changes in pricing regulation could restrict the amount charged for products.
• Uncertainty of insurance coverage and reimbursement status for newly approved products, limiting marketability and revenue generation.
• Inability to obtain and maintain adequate United States and foreign patent protection, or if the scope of protection is not sufficiently broad, allowing competitors to develop similar products.
• Third parties may initiate legal proceedings alleging infringement of their intellectual property rights, leading to uncertain outcomes and material adverse effects.
• Negative public opinion and increased regulatory scrutiny of gene therapy may damage public perception and affect business operations or regulatory approvals.
• Business operations may be subject to disputes, claims, and lawsuits, which may be costly and time-consuming.
• The increasing use of social media platforms presents new risks and challenges, including regulatory non-compliance and reputational damage.
• Unfavorable global economic and geopolitical conditions could adversely affect business, financial condition, or results of operations.
• Inadequate funding for the FDA and other government agencies, or other disruptions to their operations, could hinder product development and commercialization.
• Artificial intelligence presents risks and challenges, including data privacy, cybersecurity, intellectual property, healthcare fraud and abuse, and regulatory uncertainties.
• Business continuity and disaster recovery plans may not adequately protect from serious disasters.
• Future success depends on the ability to retain key employees and scientific advisors and to attract, retain, and motivate qualified personnel.
• Changes in U.S. patent law could diminish the value of patents in general.
• If trademarks and trade names are not adequately protected, the ability to build name recognition may be impaired.
• Efforts to enforce or protect proprietary rights may be ineffective and costly.
• Ability to use net operating loss carryforwards and certain tax credit carryforwards may be subject to limitation.
• The Chief Executive Officer and Chairman of the Board, and the Founder, President, Research & Development and Director, have the ability to substantially influence all matters submitted to stockholders for approval.
• If securities analysts publish negative evaluations of the stock, the price of the stock could decline.
• Raising additional capital could cause the price of common stock to decline and cause dilution to stockholders, restrict operations, or require relinquishing rights.
• The price of common stock may be volatile and fluctuate substantially.
• Failure to maintain effective internal control over financial reporting could adversely affect investor confidence.
• Provisions in the certificate of incorporation and bylaws, as well as Delaware law, could make an acquisition more difficult and prevent or deter stockholders from replacing current management.
• Broad discretion in the use of cash, cash equivalents, and marketable securities, which may not be used effectively.
• No anticipated cash dividends on common stock in the foreseeable future, making capital appreciation the sole source of gain.
• Issuing additional shares of common stock could cause the price of common stock to decline and cause dilution to stockholders.

Future Outlook

Krystal Biotech anticipates continued significant expenses for the foreseeable future, driven by the global commercialization of VYJUVEK and the advancement of its diverse pipeline, including manufacturing, regulatory approvals, and clinical trials. The company expects to finalize the CORAL-3 study design for KB407 and commence enrollment in the first half of 2026. Enrollment for the IOLITE study (KB803) is projected to conclude in the first half of 2026, with top-line results anticipated in late 2026. Interim data for KB408 and the inhaled KB707 combination cohort are expected in 2026, along with top-line data for EMERALD-1 (KB801). A registrational study for KB111 is planned for initiation in the second half of 2026, and a Phase 2 study for KB304 is expected to begin in 2027. The company believes its current cash, cash equivalents, and short-term investments are sufficient to fund operations for at least the next 12 months.

Management Comments

• "We believe that certain inherent features of the HSV-1 virus, combined with the modifications we have made to the viral backbone provides our proprietary gene therapy platform with specific advantages over other viral and non-viral vector platforms and represents an opportunity to generate a portfolio of highly differentiated and potentially first-in-class or best-in-class genetic medicines."
• "We believe our approach to treating DEB is positively differentiated relative to palliative approaches, which do not address the underlying genetic cause of DEB or impact the durability of wound closure, and corrective treatments that employ autologous approaches."
• "We have prioritized development of the inhaled KB707 formulation based on early clinical evidence of efficacy for the treatment of NSCLC."
• "Our management, including the Chief Executive Officer and Chief Accounting Officer, do not expect that our disclosure controls and procedures and our internal controls will prevent all error and all fraud."

Industry Context

StockSavvy.ai notes that Krystal Biotech operates in the highly competitive and rapidly evolving gene therapy and biotechnology sectors. The company's focus on rare diseases with high unmet medical needs aligns with a growing trend in the biopharmaceutical industry to develop specialized, high-value therapies. The global expansion of VYJUVEK into Europe and Japan positions Krystal Biotech to capitalize on international markets, a common strategy for companies with approved rare disease treatments. The increasing scrutiny on drug pricing and healthcare costs, as evidenced by the Inflation Reduction Act and other legislative efforts, presents a challenging reimbursement environment for novel, high-cost therapies like gene therapies. The company's investment in in-house CGMP manufacturing facilities provides a competitive advantage in quality control and supply chain management, differentiating it from many smaller biotechs reliant solely on CMOs. The use of AI platforms, while presenting risks, also reflects a broader industry trend towards leveraging advanced technologies for drug discovery and development.

Comparison to Industry Standards

• VYJUVEK is the first corrective therapy for DEB approved worldwide, setting a new standard compared to previous palliative treatments like Chiesi Farmaceutici S.p.A.'s Filsuvez (approved by FDA in 2023 and EMA).
• Abeona Therapeutics Inc.'s autologous gene therapy product Zevaskyn (prademagene zamikeracel) was approved by the FDA in 2025, indicating direct competition in the DEB market with a different approach.
• For AATD lung disease, current standard of care involves weekly IV infusions of AAT augmentation therapy from companies like CSL Limited, Takeda Pharmaceutical Company Limited, and Grifols, S.A. KB408 aims to offer a potentially less burdensome inhaled alternative.
• In Neurotrophic Keratitis, Domp farmaceutici S.p.A.'s Oxervate (cenegermin) was approved by the FDA in 2018 and EMA in 2017, requiring six times daily administration. KB801 aims for sustained NGF production via eye drops, potentially reducing treatment frequency and burden.
• In oncology, the company faces competition from established players like Merck & Co Inc., Bristol Myers Squibb Company, Johnson & Johnson, and Pfizer Inc. KB707's early Objective Response Rate of 36% and Disease Control Rate of 54% in heavily pre-treated NSCLC patients in KYANITE-1 are promising compared to typical response rates in such refractory populations, but require further validation in larger trials.
• In aesthetics, the company competes with major players like AbbVie Inc., Revance Therapeutics, Inc., Merz Pharma GmbH & Co., KGaA, and Galderma S.A., which market hyaluronic acid and botulinum toxin-based products. KB304's approach of directed expression of COL3 and ELN via intradermal injection represents a novel, potentially more fundamental biorejuvenation strategy compared to existing fillers and neuromodulators.

Corporate Governance

Legal Proceedings

• In May 2020, PeriphaGen, Inc. commenced litigation against the company alleging breach of contract and misappropriation of trade secrets. This was settled in April 2022 for an upfront payment of $25.0 million and four contingent milestone payments of $12.5 million each, totaling $75.0 million, which has been fully paid by 2025.
• In the first quarter of 2025, the company and certain of its employees received subpoenas from the U.S. Department of Justice requesting documents regarding its sponsored genetic testing program relating to VYJUVEK and commercial practices. The company is cooperating, but the amount of any loss or range of possible loss cannot be estimated with certainty.
• On September 18, 2025, a stockholder filed a derivative complaint in the Court of Chancery of Delaware naming the company's directors as defendants and the company as a nominal defendant. The complaint alleges claims for breach of fiduciary duty, unjust enrichment, and waste of corporate assets based on allegedly excessive non-employee director compensation from 2021 through 2024. The parties have reached an agreement in principle on settlement terms, which include corporate governance reforms for five years, subject to court approval.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong revenue growth and pipeline progress; risk of dilution from future capital raises; impact from stock price volatility; influence of major shareholders (Krish S. Krishnan and Suma M. Krishnan).
• Patients: Increased access to VYJUVEK globally and expanded treatment options (from birth, home administration); potential for new therapies for CF, AATD, ocular DEB, NK, HHD, and NSCLC through pipeline development.
• Employees: Significant growth in employee numbers and infrastructure; competitive compensation packages and development opportunities; risk of misconduct or non-compliance.
• Customers (HCPs, hospitals, specialty pharmacies): Continued reliance on their distribution and administration capabilities; need for education on new therapies.
• Suppliers: Dependence on a limited number of third-party suppliers for raw materials and components, posing supply chain risks.
• Regulatory Authorities: Ongoing interactions for approvals, compliance, and post-marketing requirements; increased scrutiny on gene therapy and drug pricing.

Next Steps

• Further expand the specialty distributor network during 2026.
• Advance pricing discussions with Italian reimbursement authorities to enable a potential VYJUVEK launch in the second half of 2026.
• Initiate pricing discussions with relevant authorities in other key Western European markets.
• Prepare regulatory filings for marketing authorization of B-VEC in the United Kingdom and Switzerland.
• Align on the CORAL-3 study design with the FDA and start enrollment in the potentially registrational CORAL-3 study for KB407 (CF) in the first half of 2026.
• Report interim safety and SERPINA1 delivery data from the repeat dose Cohort 2B of SERPENTINE-1 (KB408) in 2026.
• Complete enrollment in the IOLITE study (KB803) in the first half of 2026 and report top-line results later in 2026.
• Complete development and validation of an HHD-specific evaluation scale in the first half of 2026 for KB111.
• Initiate a registrational, intra-patient randomized, double-blind, placebo-controlled, multi-center study evaluating KB111 for the treatment of HHD in the second half of 2026.
• Report top-line data for EMERALD-1 (KB801) in 2026.
• Report interim efficacy data and potential registrational study plans for the inhaled KB707 combination cohort in KYANITE-1 in 2026.
• Evaluate aesthetic indications most suitable for advanced clinical development of KB301.
• Initiate a Phase 2 study for KB304 in 2027.
• Conduct exploratory preclinical research and development to expand potential applications of the proprietary HSV-1 based vector platform.
• Seek collaborative alliances towards the development and potential commercialization of therapies for more common conditions.
• Continue to follow patients enrolled in OPAL-1 (intratumoral KB707) and adjust development plans based on safety and efficacy results.

Key Dates

Recommendation

Krystal Biotech demonstrates robust commercial success with VYJUVEK, evidenced by significant revenue growth and high gross margins, coupled with successful global market expansion. The company's deep and advancing pipeline, particularly with multiple candidates entering or progressing through registrational trials and receiving expedited designations, signals strong future growth potential. The resolution of federal net operating losses and the release of a substantial deferred tax asset valuation allowance further strengthen the financial outlook. While increased operating expenses and ongoing pricing negotiations in some markets are noted, the overall trajectory of commercialization and pipeline development presents a compelling investment case for long-term growth in the gene therapy sector.

Keywords

Krystal Biotech, gene therapy, VYJUVEK, dystrophic epidermolysis bullosa, DEB, rare disease, genetic medicine, HSV-1 vector, biotechnology, clinical trials, FDA approval, EMA approval, MHLW approval, cystic fibrosis, CF, alpha-1 antitrypsin deficiency, AATD, neurotrophic keratitis, NK, Hailey-Hailey disease, HHD, non-small cell lung cancer, NSCLC, oncology, dermatology, ophthalmology, aesthetics, manufacturing, CGMP, financial results, revenue, net income, pipeline, R&D, intellectual property